# Hepregen Corporation

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/hepregen

- Industry: Biotechnology
- Headquarters: Medford, US
- Website: www.hepregen.com
- Total disclosed funding: $3M
- Latest round: Series A (Jun 1, 2008)
- Investors on record: 1

## About

Hepregen Corporation specializes in advanced cell-based technology solutions aimed at improving drug safety and efficacy through innovative liver cell culture systems.Founded in 2007 and headquartered in Medford, US, Hepregen Corporation focuses on developing liver cell culture systems for drug testing. The company has made four deals to date, with its most recent deal occurring on June 27, 2012, when it secured USD 0.5 mn in Grant funding from the National Science Foundation. Jeffrey Janus is the founder of Hepregen Corporation.Hepregen Corporation offers a range of cell-based technology solutions primarily designed for pharmaceutical companies. Their products include liver cell culture systems that enhance drug testing processes, aiming to optimize drug safety and efficacy. These systems are marketed to a global clientele, supporting the pharmaceutical industry's demands for reliable and efficient testing solutions.The company generates revenue through the sale of its liver cell culture technology, providing various services to pharmaceutical companies that require high-quality testing systems. Their pricing strategy is structured to accommodate different client needs, enabling a consistent revenue stream from recurring contracts.Hepregen Corporation plans to leverage its recent Grant funding of USD 0.5 mn to accelerate the development of new liver cell culture products aimed at enhancing drug testing capabilities. The company is exploring expansion into European and Asian markets by 2025, intending to broaden its customer base and improve access to its innovative solutions for pharmaceutical research.

## Funding rounds

- Series A, Jun 1, 2008, $3M — Battelle Ventures

## Investors

- Battelle Ventures (https://capitalatlas.ai/funds/battelle-ventures) — Series A